Pfizer.com receives first makeover in three years

Share this article:
Pfizer has launched a refreshed consumer Web site featuring a cleaner design and new features.

“I think the site is warmer and more emotional in tone than the previous one, and it's reflective of what we've heard from our survey (of users),” Pfizer spokesman Andy McCormick told MM&M.
For Pfizer.com's first Web site makeover in nearly three years, the company worked with Grey unit G2 Direct and Digital to incorporate a product search on every single page.

“We've made it easier for our users to access our updated product information,” Pfizer spokeswoman Kate Bird added. “We've also incorporated a technology called Ajax, which is a combination of JavaScript and XML. That gives us the opportunity to highlight and promote certain events and programs without taking the user several clicks into the site.”

Other new Pfizer.com features include automated Securities and Exchange Commission filings and a more robust investor dashboard for Pfizer's investor population.

Also, a new R&D section features information on Pfizer's product pipeline as well as post-marketing commitments that are updated on a weekly basis.

Pfizer.com averages about 4 million visitors per year. That audience is comprised of both consumers and healthcare professionals, according to Bird.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...